GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Basic Sciences/The Protein Denitrosylase SCoR2 Regulates Lipogenesis and Fat Storage

The Protein Denitrosylase SCoR2 Regulates Lipogenesis and Fat Storage

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

Yes, the protein denitrosylase SCoR2 (SNO–CoA reductase 2) plays a central role in regulating lipogenesis (the process of lipid synthesis) and fat storage, as revealed in the research article. SCoR2 is proposed to act as a metabolic regulator, akin to sirtuins, but through controlling protein S-nitrosylation rather than acetylation.


Yes, the protein denitrosylase SCoR2 (SNO–CoA reductase 2) plays a central role in regulating lipogenesis (the process of lipid synthesis) and fat storage, as revealed in the research article. SCoR2 is proposed to act as a metabolic regulator, akin to sirtuins, but through controlling protein S-nitrosylation rather than acetylation.

Here is a detailed explanation of how SCoR2 regulates lipogenesis and fat storage:

### 1. **Role in Adipose Tissue:**

  • **Promotion of Fat Storage:** SCoR2 promotes fat storage by denitrosylating the cytoskeletal regulator myosin 9 (Myh9). This denitrosylation suppresses actomyosin assembly, which is essential for enabling the activation of key lipogenic transcription factors.
  • **Activation of Lipogenic Transcription Factors:** These transcription factors include PPARγ, SREBP1, and CEBPα, which are vital for adipocyte differentiation and lipid synthesis. By activating these factors, SCoR2 drives the processes that lead to fat accumulation in adipose tissue.
  • **Impact of SCoR2 Loss or Inhibition:** When SCoR2 is lost or inhibited, the S-nitrosylation of Myh9 increases, disrupting the transcriptional programs required for lipogenesis. This limits the expansion of adipose tissue, effectively reducing fat storage.

### 2. **Role in the Liver:**

  • **Targeting Lipogenic Enzymes:** In the liver, SCoR2 directly targets enzymes involved in de novo lipogenesis, such as ATP citrate lyase (ACLY) and fatty acid synthase (FASN). These enzymes are critical for synthesizing lipids.
  • **Effect of Inhibition or Deletion:** When SCoR2 is inhibited or deleted, it increases the S-nitrosylation of ACLY and FASN, thereby reducing lipid synthesis. At the same time, this inhibition promotes fatty acid oxidation, which helps to break down fats.
  • **Protection Against Fat Accumulation:** This dual effect of reduced lipid synthesis and increased fat oxidation protects the liver from fat accumulation and injury, which are hallmarks of metabolic dysfunction–associated steatotic liver disease (MASLD).

### 3. **SCoR2 as a Therapeutic Target:**

  • The study identifies SCoR2 as a promising therapeutic target for obesity and MASLD. By targeting SCoR2, it may be possible to simultaneously limit lipid synthesis, enhance fat oxidation, and improve overall metabolic health.
  • This approach could address the root causes of excess lipid accumulation in adipose tissue and liver, which are central to the development of obesity and related metabolic disorders.

### Conclusion:

SCoR2 regulates lipogenesis and fat storage through its denitrosylase activity, influencing key molecular pathways in both adipose tissue and liver. Its role as a metabolic regulator highlights its potential as a target for therapeutic strategies aimed at combating obesity, MASLD, and other lipid-related metabolic dysfunctions.

Related Q&A

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer